NASDAQ : PCVX
Vaxcyte, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 62.03 USD (Oct 30, 2026, 4:00 PM EST) · Market cap 9.76B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 9.55B |
| Enterprise Value | 8.18B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 157.39M |
| Shares Outstanding | 157.39M |
| Shares Change (YoY) | +4.88% |
| Shares Change (QoQ) | +3.58% |
| Owned by Insiders (%) | 0.59% |
| Owned by Institutions (%) | 100.41% |
| Float | 144.98M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 3.26 |
| P/TBV Ratio | 3.45 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 5.72 |
| Quick Ratio | 5.48 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -36.51% |
| Return on Assets (ROA) | -22.61% |
| Return on Invested Capital (ROIC) | -24.15% |
| Return on Capital Employed (ROCE) | -40.65% |
| Weighted Average Cost of Capital (WACC) | 10.91% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.10M |
| Employee Count | 507 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.23 |
| 52-Week Price Change | +34.43% |
| 50-Day Moving Average | 61.57 |
| 200-Day Moving Average | 57.10 |
| Relative Strength Index (RSI) | 46.40 |
| Average Volume (20 Days) | 3,271,100 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 14.62M |
| Short Previous Month | 17.29M |
| Short % of Shares Out | 9.29% |
| Short % of Float | 10.09% |
| Short Ratio (days to cover) | 4.40 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -1.17B |
| Pretax Income | -1.06B |
| Net Income | -1.06B |
| EBITDA | -1.15B |
| EBIT | -1.17B |
| Earnings Per Share (EPS) | -$7.65 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 1.49B |
| Total Debt | 115.45M |
| Net Cash | 1.37B |
| Net Cash Per Share | $8.71 |
| Equity (Book Value) | 2.76B |
| Book Value Per Share | 19.05 |
| Working Capital | 1.28B |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -881.23M |
| Capital Expenditures | -39.84M |
| Depreciation & Amortization | 16.51M |
| Net Borrowing | n/a |
| Free Cash Flow | -921.07M |
| FCF Per Share | -$5.85 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -4.88% |
| Shareholder Yield | -4.88% |
| Earnings Yield | -12.60% |
| FCF Yield | -9.68% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $117.30 |
| Price Target Difference | 93.31% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |